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Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre Itine ´rAIR-Scle ´rodermie cohort of
patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline.
Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified
as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was
estimated using the Kaplan–Meier method. Multivariate survival analyses were conducted using the Cox model.
Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of
patients were female, with lcSSc, mean age 54.9 13.0 years and mean duration of SSc of 8.8 8.1 years. In total, 47 patients died, giving a
3-year survival of 91.1% and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2%) resulted from pulmonary arterial
hypertension (PAH) and eight (17.1%) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival
of 56.3%. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and
Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality.
Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR
for mortality in patients with SSc, justifying yearly echocardiographic screening.
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Introduction
During recent decades, the survival of patients with SSc has
improved considerably, largely as a result of improvements in the
treatment of SSc renal crisis. Changes have also been observed
within this time period in the pattern of deaths attributed to
organ-specific manifestations of SSc. Steen and Medsger [1]
recently documented these changes in causes of mortality in SSc
patients from a single centre during the past 25 years. The 10-year
survival rate was observed to improve steadily from 54% to 66%
between the 1980s and the current era [1]. In addition, the
frequency of deaths due to renal crisis has decreased dramatically,
with pulmonary fibrosis and pulmonary arterial hypertension
(PAH) having emerged as the current leading causes of
mortality [1].
We recently conducted a prospective, multicentre study to
estimate the prevalence of PAH in SSc patients without severe
pulmonary fibrosis or severe left heart disease [2]. Our screening
programme estimated the frequency of PAH to be 7.85% in a
population of 599 patients. We also demonstrated that a screening
algorithm based on dyspnoea, Doppler echocardiographic evalua-
tion of the velocity of tricuspid regurgitation (VTR) and right-
heart catheterization enabled early detection of PAH at a mild
stage [2]. A 3-year longitudinal follow-up of this cohort was
planned and conducted in order to estimate survival, to describe
causes of death and to individualize factors associated with
survival in patients with SSc. The results of this study are reported
here.
Methods
Patients
A total of 21 French university hospitals experienced in the
management of SSc participated in the Itine ´ rAIR-Scle ´ rodermie
study [2]. One centre did not participate in the collection of the
3-year follow-up data; therefore, the present study involved 20
centres. Patients with SSc who fulfilled the ACR criteria who
visited participating hospitals between September 2002 and July
2003 for regular follow-up visits were invited to enter the study
[2, 3]. Patients were classified as having lcSSc or dcSSc according
to Le Roy et al. [4]. Since the Itine ´ rAIR-Scle ´ rodermie study was
primarily implemented for the investigation of PAH, for the sake
of homogeneity, patients who were considered to be more prone
to developing other types of pulmonary hypertension (PH) were
not enrolled. These included patients with severe left-heart disease
at baseline (defined as left ventricular ejection fraction <45%,
mitral or aortic regurgitation >grade 2, mitral area <1.5cm
2 or
aortic area <1cm
2) who were considered to be at risk of devel-
oping post-capillary PH. Patients with severe restrictive lung
disease at baseline [defined as forced vital capacity (FVC) or total
lung capacity (TLC) <60% of the predicted] who were considered
to be at risk of developing PH associated with severe pulmonary
fibrosis were also excluded.
Data collected at baseline
Patient demographics, SSc characteristics (including history since
first symptoms and occurrence of RP), Rodnan skin score [5] and
signs and symptoms evocative of PAH were collected at baseline.
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expiratory volume in 1 (FEV1)/FVC, diffusing capacity for
carbon monoxide (DLCO), and blood gases were also repeated
at baseline, unless performed within the previous 6 months. The
presence of ANAs, including anti-topo-isomerase and anti-
centromere antibodies was investigated.
Data collected at follow-up visits
Data pertaining to cardiovascular risk factors (tobacco consump-
tion, diabetes mellitus, hypertension, hypercholesterolaemia),
Rodnan skin score and presence or absence of digital ulcers
were collected. Each patient underwent a 12-lead electrocardio-
gram. Pulmonary function tests were recommended to be repeated
every year. If a patient died since the last performed visit, the date
and cause of death were collected.
Patients lost to follow-up
Each participating physician was asked to make an effort to
document the vital status of the patient both annually and at the
end of the 3-year follow-up period. If no contact with patients
could be established, a query was sent to the registry of births and
deaths at their regional city hall.
Diagnosis of PAH
Patients with a confirmed diagnosis of PAH were identified at
baseline. The remaining patients were screened for PAH at base-
line and on a regular basis during the follow-up period using
an algorithm that included evaluation of dyspnoea based on
the modified New York Heart Association functional class and
Doppler echocardiographic evaluation of VTR [2]. Diagnosis of
PAH was confirmed using right heart catheterization (RHC).
PAH was defined as a mean pulmonary arterial pressure
525mmHg at rest or 530mmHg during exercise, with mean
pulmonary arterial wedge pressure <15mmHg on RHC.
Statistical methods
Statistical analyses were performed using SAS software version
9.1 (SAS Institute, Cary, NC, USA). Data are expressed as mean
(S.D.) for continuous variables and as number (percentages) for
categorical variables. The follow-up duration was determined to
be the time elapsed from entry into the study until the date of last
news (last visit or death). Data were censored at 37 months, the
time of death or loss to follow-up, whichever was earlier. The
duration between study entry and last news was plotted using
the Kaplan–Meier method. The cumulative incidence of deaths
was calculated as the ratio of the number of deceased patients over
the duration of follow-up expressed in patient-years. The CI of the
cumulative incidence was calculated by dividing the Gaussian
confidence interval of the number of events by the duration of
follow-up expressed in patient-years.
Causes of death were classified as ‘SSc-related’ (SSc renal crisis,
PAH, pulmonary fibrosis, gastrointestinal, cardiac and multi-
organ failure) or ‘non SSc-related’ (cancer, atherosclerotic, cardio-
vascular and cerebrovascular disease, infection, sudden death,
other) or unknown, by the same method as Steen and Medsger [1].
The association between centre or baseline characteristics and the
risk of mortality were explored using univariate and multivariate
analyses. For each test, hazard ratios (HRs) and their 95% CIs
were identified. Variables associated with outcome at P<0.20
were included in a multivariable Cox model with the forward step-
wise option. The significance level for removing a variable from
the model was set at P>0.05. For interval-independent variables,
the assumption that the logarithm of HR changed linearly with
each unit change was assessed graphically. The assumption that
HR was constant over time was assessed by proportionality test
using time-dependent derived variables for each variable retained
in the model. Furthermore, for binary variables, log-minus-log
survival was plotted showing a constant difference between strata.
Goodness of fit was assessed by likelihood ratio. Deviance
residuals were plotted against each variable retained in the
model. Martingale residuals and deviance residuals were plotted
against the linear predictor scores.
Ethical approval
The study was approved by an independent review board (Comite ´
de Protection des Personnes of Lille, France). Informed consent
was obtained from every patient at study entry and at each follow-
up visit. Analysis of data was conducted independently under the
supervision of a multidisciplinary scientific committee.
Results
Patient demographics and baseline characteristics
From a total of 599 patients enrolled in the original Itine ´ rAIR-
Scle ´ rodermie cohort, 550 patients agreed to participate in the
3-year follow-up. One centre and four patients from the remaining
20 centres declined to participate; a further four patients were lost
to follow-up. Therefore, the analysis of survival was conducted on
546 patients.
Baseline characteristics of these patients are summarized in
Table 1. Despite the exclusion from the study of patients with
TABLE 1. Characteristics of patients at baseline
Parameter All patients (n¼546) Patients who died during follow-up (n¼47) Patients alive at end of follow-up (n¼499)
Mean age  S.D., years 54.9 13.0 62.8 14.0 54.1 12.6
Male, n (%) 87 (15.9) 15 (31.9) 72 (14.4)
Mean age at first non-RP symptom   S.D., years 46.0 13.7 52.9 15.0 45.4 13.4
Mean age at SSc diagnosis   S.D., years 47.8 13.7 54.6 15.0 47.2 13.4
Mean time since first onset of RP   S.D., years 14.6 12.4 14.9 11.7 14.6 12.5
Mean time since first non-RP symptom   S.D., years 8.8 8.1 9.9 8.4 8.7 8.1
dcSSc, n (%) 150 (27.5) 21 (44.7) 129 (25.9)
Mean Rodnan skin score   S.D. 13.2 10.6 19.6 14.0 12.6 10.0
Moderate dyspnoea (NYHA FC II), n (%) 141 (25.8) 18 (38.3) 123 (24.6)
Severe dyspnoea (NYHA FC III–IV), n (%) 59 (10.8) 17 (36.2) 42 (8.4)
VTR  2.8m/s, n (%) 69 (12.6) 15 (31.9) 54 (10.8)
PAH at baseline, n (%) 47 (8.6) 20 (42.6) 27 (5.4)
Basal pulmonary fibrosis, n (%) 86 (15.8) 14 (29.8) 72 (14.4)
Prior digital ulcer(s), n (%) 280 (51.3) 26 (55.3) 254 (50.9)
TLC <80% of the predicted value, n (%) 79 (16.6)
a 14 (43.8)
b 65 (14.6)
c
FVC <80% of the predicted value, n (%) 71 (14.1) 14 (29.8) 57 (11.4)
DLCO <60% of the predicted value, n (%) 122 (25.0)
d 16 (55.2)
e 106 (23.0)
f
Anti-topoisomerase antibodies, n (%) 136 (28.0)
g 14 (40.0)
h 122 (27.1)
i
Anti-centromere antibodies, n (%) 234 (51.9)
j 21 (61.8)
k 213 (47.1)
l
an¼477;
bn¼32;
cn¼445;
dn¼489;
en¼29;
fn¼460;
gn¼486;
hn¼34;
in¼452;
jn¼486;
kn¼35;
ln¼451. NYHA FC: New York Heart Association functional class.
Survival in SSc patients 305severe pulmonary function impairment, 15.8% of the patients
exhibited basal pulmonary fibrosis at baseline; TLC and FVC were
observed to be between 60% and 80% of the predicted values in
16.6% and 14.1% of the patients, respectively. DLCO at baseline
was <60% of the predicted values in 25% of the patients.
Survival and causes of death
The median duration of follow-up was 37 months, representing a
total of 1547 patient-years. A total of 47 patients died during the
follow-up period, giving a cumulative mortality rate of 3.04 deaths
per 100 patient-years (95% CI 2.17, 3.90). The 3-year Kaplan–
Meier estimate of survival was 91.1% in the whole population.
When stratified according to the absence or presence of PAH,
observed survival estimates were 94.4% in patients without PAH
at baseline and 56.3% in patients with PAH at baseline (Fig. 1).
Causes of death were SSc-related in 24 patients (51.1% of all
causes of death; Table 2). Eight patients died of cancer with all
except one patient having a form of intrathoracic cancer: four
patients died from lung cancer, one from pleural cancer, one from
a mediastinal tumour, one from pulmonary metastases of an
unknown primary cancer and one died from breast cancer. Six of
these patients were never smokers and one had ceased smoking
some years previously. The two leading causes of death were PAH
and cancer, which accounted for 32.2% and 17.1% of deaths,
respectively (42.5% and 20.5%, respectively for known causes of
death). Renal crisis accounted for 6.4% of the deaths (7.7% for
known causes of death).
Associations between baseline characteristics and mortality
Results of univariate analyses are given in Table 3. Baseline
measurements of DLCO and VTR were strongly associated with
survival. The 3-year Kaplan–Meier survival estimate was 96.3%
among patients with baseline DLCO >60% of the predicted values
vs 87.4% among patients with baseline DLCO <60% of the
predicted values (P<0.0001). Similarly, the 3-year Kaplan–Meier
survival estimate was 95.5% among patients with VTR <2.8m/s
vs 77.5% among patients with VTR 52.8m/s (P<0.0001). Centre
was not associated with outcome (data not shown).
Following a multivariate analysis, the presence of PAH [HR
7.246 (95% CI 4.000, 13.158)], age at first non-RP symptom [HR
1.052/year (95% CI 1.025, 1.080)], duration of SSc [HR 1.047/year
(95% CI 1.008, 1.087)] and Rodnan skin score (per one point)
[HR 1.045 (95% CI 1.023, 1.066)] were observed to be significant
predictive factors for mortality (Table 4). Neither SSc subtype nor
the extent of dyspnoea was identified by this technique to be
associated with mortality. DLCO was not available for all patients
at entry and was therefore not investigated in the multivariate
analysis. A VTR 52.8m/s was introduced in a further model in
lieu of PAH. In this model, VTR 52.8m/s and Rodnan skin score
were both associated with a higher risk of mortality [HR 5.368
(95% CI 2.62, 11.01) and 1.04 (95% CI 1.01, 1.09), respectively].
Discussion
This study was a 3-year follow-up of a large, multicentre cohort of
patients with SSc in France and was designed to investigate the
survival rates, causes of death and factors associated with survival
in SSc. A total of 546 patients with SSc and without severe
pulmonary fibrosis or left heart disease at baseline were followed
for a median duration of 37 months, representing 1537 patient-
years. We have estimated the 3-year Kaplan–Meier survival to be
91.1% and the cumulative mortality of these patients to be 3.04
deaths per 100 patient-years. The roles of PAH and cancer among
the leading causes of death were also confirmed. A VTR 52.8m/s
and DLCO <60% of predicted values at baseline were observed
to be strongly associated with poor prognosis. A multivariate
analysis illustrated that PAH was a major risk factor for death,
with an HR of 7.246.
FIG. 1. Kaplan–Meier estimate of survival vs time stratified according to PAH at
baseline.
TABLE 3. Risk of death associated with baseline characteristics (univariate
analysis)
Parameter
Univariate analysis
HR (95% CI) p
Male sex 2.60 (1.41, 4.81) 0.002
Age (per year) 1.06 (1.03, 1.09) <0.0001
Age at first non-RP symptom (per year) 1.04 (1.02, 1.07) 0.0003
Time since first SSc sign (per year) 1.01 (0.98, 1.05) 0.39
dcSSc 2.21 (1.24, 3.92) 0.007
Rodnan skin score (per 1 point) 1.04 (0.94, 0.98) <0.0001
Moderate dyspnoea (NYHA FC II) 2.45 (1.29, 4.67) 0.007
Severe dyspnoea (NYHA FC III-IV) 4.15 (1.93, 8.93) 0.0003
VTR  2.8 m/s 5.74 (2.81, 11.75) <0.0001
PAH at baseline 10.41 (5.81, 18.52) <0.0001
DLCO <60% of predicted (per 1%) 1.05 (1.03, 1.08) <0.0001
TLC (percentage of predicted) 95 (93, 98) <0.0001
FVC (percentage of predicted) 96 (94, 98) <0.0001
Anti-topoisomerase antibodies 0.58 (0.30, 1.14) 0.12
Anti-centromere antibodies 0.56 (0.28, 1.11) 0.10
NYHA: New York Heart Association functional class.
TABLE 2. Causes of death observed in the total population
Causes of death, n (%) All patients (n¼546)
Total number of deaths 47 (8.6)
Scleroderma-related causes of death 24 (4.4)
PAH 17
Pulmonary fibrosis 2
Gastrointestinal 2
Renal crisis 3
Non-scleroderma-related causes of death 23 (4.2)
Cancer 8
Infection 4
Cardiovascular or cerebrovascular atherosclerosis 2
Other cause 2
Unknown cause 7
TABLE 4. Risk of mortality associated with baseline characteristics (multivariate
analysis)
Parameter S.E.  
2 P HR (95% CI)
Age at first non-RP
symptom, years
0.051 0.013 14.440 0.0001 1.052 (1.025, 1.080)
Duration of SSc 0.046 0.019 5.722 0.016 1.047 (1.008, 1.087)
PAH at baseline 1.979 0.302 42.909 <0.0001 7.246 (4.000, 13.158)
Rodnan skin score
(per 1 point)
0.0436 0.0104 17.392 <0.0001 1.045 (1.023, 1.066)
306 Eric Hachulla et al.The 5-year survival of patients with SSc has been reported to lie
between 34% and 73%, with mortality estimated to be four times
greater than that of the general population [6]. More recent
reports, however, have suggested that survival may be greater
than that previously estimated ( 65–70% at 10 years) [1, 7, 8].
Such an improvement in prognosis may result from earlier
diagnosis, a multidisciplinary approach to treatment of the
disease, a greater awareness of expert opinion in the treatment
of patients, and the use of angiotensin-converting enzyme
inhibitors in the treatment of SSc renal crisis in the current era.
The patients in the present study were enrolled by 20 scleroderma
expert centres in France and reflect a SSc population without
severe lung fibrosis or severe left heart disease at entry. The
cumulative mortality observed in this study of 3.04 deaths per 100
patient-years is in accordance with recent reports and is very close
to the rate of 2.49 deaths per 100 patient-years observed in a
Spanish study [7].
The proportion of deaths attributed to SSc observed in this
study (51.1%) is highly comparable with the 50% observed by
Steen and Medsger [1], despite the present study having excluded
patients with severe lung fibrosis at entry. The main cause of death
in our study was PAH, with a cumulative mortality of 19.6 deaths
per 100 patient-years in the 47 patients with PAH known or
screened at entry. This observation supports the increasing impact
of this complication on the survival of patients with SSc. The poor
prognosis of SSc patients with PAH emphasizes the need for
physicians to follow international and European guidelines, which
recommend the systematic, annual screening of SSc patients for
PAH using Doppler echocardiography [9, 10]. Although SSc renal
crisis is no longer a leading cause of death, three out of 546
patients died as a result of this manifestation.
Among the non-SSc-related causes of death, cancers—particu-
larly lung cancer—appear to play a major role, an observation
that has been reported previously [1, 8]. Tobacco use has been
reported to increase the risk of lung cancer in SSc patients by
7-fold [11]. It should be noted, however, that none of the four
patients in this study who died from lung cancer were current or
former smokers. Among the four patients who died from lung
cancer in the present study, basal lung fibrosis was present in only
one. Previous studies have suggested that patients with SSc are at
an increased risk of cancer vs the general population [12, 13],
and the role of pulmonary fibrosis in lung cancer is still subject
to debate. Our results support the monitoring of SSc patients
for lung cancer. The cessation of tobacco use and limitation of
exposure to X-rays may also be beneficial.
Among factors associated with survival, SSc subtype, DLCO
and overall VTR should be highlighted. Whereas dcSSc and
Rodnan skin scores were associated with poorer survival in
univariate analysis, only Rodnan skin score was retained in the
multivariate Cox model. This may have resulted from our deci-
sion to exclude patients with severe lung disease. Our data also
demonstrate that a DLCO <60% of predicted values at baseline is
associated with increased mortality. In our population, a severely
altered DLCO may indicate significant pulmonary vascular
disease, since patients with severe interstitial lung disease were
excluded at baseline.
Our findings also suggest that VTR can be used to identify
patients at greater risk of mortality. In a screening programme for
PAH performed in patients with sickle cell disease, Gladwin et al.
[14] observed that mortality was higher in patients with a VTR
>2.5m/s. We found no difference in survival between patients
with a VTR <2.5m/s vs those with VTR within the 2.5–2.8m/s
range. Conversely, patients with a VTR 52.8m/s were observed
to exhibit poorer prognosis with an HR of 5.74 in univariate
analysis. When introduced in the multivariate model in lieu of
PAH, VTR 52.8m/s was a strong predictor of death with an HR
of 5.37. Our observations support the hypothesis that a VTR
threshold of 52.8m/s is more accurate than one of 52.5m/s in
predicting survival in SSc patients. However, this VTR threshold
is not specific to PAH, as post-capillary PH can also be diagnosed
by RHC even in the absence of left ventricular abnormalities on
echocardiography [2, 15].
While this study provides important observations, there are a
number of theoretical limitations that must be acknowledged. The
exclusion at entry of patients with severe lung fibrosis or with
severe left heart disease may have led to an underestimation of
SSc-related cause of death. Another potential limitation is that
one of the centres from our original Itine ´ rAIR-Scle ´ rodermie study
did not participate in the 3-year follow-up, and that an unknown
pool of SSc patients followed by non-specialist centres may also
exist. In addition, there may be differences in the referral pattern
between the participating centres.
In conclusion, we observed a 3-year Kaplan–Meier estimate for
survival of 91.1% in our population of SSc patients, and of 56.3%
in patients with PAH at baseline. The cumulative mortality rate of
patients with SSc observed in our multicentre cohort was 3.04
deaths per 100 patient-years, despite the exclusion of SSc patients
with severe pulmonary fibrosis or severe left heart disease at
baseline. Our observations have underlined the leading roles of
PAH and cancer in mortality among patients with SSc. The
development of PAH was observed to increase the HR for
mortality in patients with SSc by more than 7-fold during a 3-year
period. We consider that the poor prognosis of SSc patients with
PAH justifies a yearly echocardiographic screening.
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Appendix
List of Itine´rAIR-Scle´rodermie investigators in alphabetical
order by city
Bordeaux 1: Jean-Franc ¸ ois Viallard, Marie-Sylvie Doutre, Thierry
Schaeverbeke, Marc-Alain Bille ` s, Patricia Re ´ ant and Claire
Dromer; Bordeaux 2: Joe ¨ l Constans, Philippe Gosse and
Philippe Lemetayer; Clamart, Antoine-Be ´ cle ` re: Marc Humbert,
Olivier Sitbon, Xavier Jaı¨s, Abdul Monem Hamid, Vincent Ioos
and Ge ´ rald Simonneau; Cre ´ teil, Henri-Mondor: Anne Cosnes and
Ce ´ cile Roiron; Grenoble: Patrick Carpentier, Jean-Luc
Cracowski, Carole Saurier, Muriel Salvant, Carole Schwebel
and Christophe Pison; Lille: Eric Hachulla, Pierre-Yves Hatron,
David Launay, Viviane Queyrel, Marc Lambert, Sandrine
Morell-Dubois, Hilaire Charlanne, Pascal de Groote and
Nicolas Lamblin; Lyon: Jacques Ninet, Fadi Jamal, Genevie ` ve
De ´ rumeaux and Jean-Yves Bayle; Marseille: Jean-Robert Harle,
Fre ´ de ´ rique Retornaz, Gilbert Habib, Se ´ bastien Renard and
Martine Reynaud-Gaubert; Nancy: Daniela Cirstea, Jean-
Dominique de Korwin, Christine Suty-Selton and Franc ¸ ois
Chabot; Nantes: Christian Agard, Mohamed Hamidou, Jean-
Pierre Gueffet, Patrice Gue ´ rin, Erwan Bressolette and Alain
Haloun; Paris, Bichat: Thomas Papo, Olivier Lidove, Catherine
Picard-Dahan and David Messika-Zeitoun; Paris, Cochin 1:
Andre ´ Kahan, Yannick Allanore, Laure Cabanes and Christian
Spaulding; Paris, Cochin 2: Loı¨c Guillevin, Luc Mouthon and
Alice Berezne ´ ; Paris, La Pitie ´ –Salpe ˆ trie ` re: Camille France ` s, Salim
Trad, Emmanuel Molinari, Anne-Claude Koeger and Dominique
de Zuttere; Paris, Saint-Antoine: Jean Cabane, Kiet Phong Tiev,
Ste ´ phanie Ederhy, Nadjib Hammoudi and Mohamed Ziani;
Paris, Saint-Joseph: Isabelle Lazareth, Ulrique Michon-Pasturel,
Yara Antakly-Hanon and Jacques Serfati; Paris, Saint-Louis:
Dominique Farge and Suzanne Me ´ nasche ´ ; Rennes: Patrick Jego,
Jacqueline Chevrant-Breton and Marcel Laurent; Strasbourg:
Jean Sibilia, He ´ le ` ne Petit and Ari Chaouat; Toulouse: Daniel
Adoue, Nathalie Blot-Souletie and Bruno Degano; and Tours:
Elisabeth Diot, Laurent Machet, Fre ´ de ´ ric Patat, Christian
Marchal and Ce ´ dric Giraudeau.
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